Lakefront Biotherapeutics NV (LKFT) Income Statement
LKFT 2025 at a glance
Fiscal year ended December 31, 2025 · eurosLKFT revenue and net income
Where LKFT's revenue goes
2025Each bar shows an amount and its share of revenue. LKFT kept 28.9% of revenue as net income.
LKFT profit margins
LKFT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +303.5% | +66.4% | — | — |
| Gross profit | +349.6% | +64.9% | — | — |
| Operating income | — | — | — | — |
| Net income | +333.1% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
LKFT income statement in euros
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | €1.11B | €275.6M | €239.7M | €241.2M | €234.4M |
| Cost of revenue | €29.7M | €34.9M | €0 | €0 | €320.5M |
| Gross profit | €1.08B | €240.8M | €239.7M | €241.2M | −€86.1M |
| Research & development | €459.4M | €335.5M | €241.3M | €269.8M | €320.5M |
| Sales, general & admin | €112.0M | €96.9M | €92.5M | €103.3M | €127.7M |
| Total operating expenses | €581.1M | €429.1M | €328.0M | €372.3M | €85.4M |
| Operating income | €501.4M | −€188.3M | −€88.3M | −€131.1M | −€171.6M |
| Interest income | €46.3M | €89.8M | €79.6M | €18.1M | — |
| Interest expense | €2.2M | €911,000 | €1.8M | €9.2M | €8.7M |
| Income before taxes | €300.9M | −€3.1M | €5.6M | −€70.8M | −€119.4M |
| Income taxes | −€18.6M | −€1.8M | €9.6M | €572,000 | €1.4M |
| Net income | €320.9M | €74.1M | €211.7M | −€218.0M | −€103.2M |
| EBITDA | €359.0M | €43.3M | €51.0M | €3.9M | −€163.3M |
| Gross margin | 97.3% | 87.4% | 100.0% | 100.0% | −36.7% |
| Operating margin | 45.1% | −68.3% | −36.8% | −54.3% | −73.2% |
| Net margin | 28.9% | 26.9% | 88.3% | −90.4% | −44.0% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | €12.1M | €6.5M | €900.8M | €71.2M | €65.3M | €75.0M | €75.5M | €59.8M | €77.9M | €62.4M | €0 | €120.0M |
| Cost of revenue | €34.6M | €4.8M | €455,000 | €10.8M | €4.7M | €13.7M | €112.9M | €93.1M | €90.2M | −€261.3M | €84.4M | €317.9M |
| Gross profit | −€22.5M | €1.7M | €900.4M | €60.3M | €60.6M | €61.2M | −€37.4M | −€33.2M | −€12.3M | €323.7M | −€124.7M | −€197.9M |
| Research & development | €25.5M | €31.0M | €107.5M | €73.9M | €95.3M | €182.8M | €97.2M | €93.0M | €73.6M | €72.3M | €70.9M | €100.3M |
| Sales, general & admin | €20.1M | €35.5M | €9.0M | €42.5M | €22.5M | €39.6M | €33.0M | €26.2M | €29.0M | €31.1M | €31.1M | €30.7M |
| Total operating expenses | €21.0M | €65.4M | €141.6M | €102.0M | €117.6M | €220.0M | €25.3M | €21.1M | €25.9M | €356.9M | −€224.2M | −€167.6M |
| Operating income | −€43.5M | −€63.7M | €758.8M | −€41.7M | −€57.0M | −€158.7M | −€81.0M | −€54.3M | −€38.2M | −€33.1M | −€69.3M | −€30.2M |
| Interest income | €12.7M | €13.6M | — | — | €10.0M | €12.6M | — | — | — | — | — | — |
| Interest expense | €281,585 | — | — | — | — | — | — | — | — | — | — | — |
| Income before taxes | €2.0M | €14.0M | €783.2M | −€221.5M | −€104.4M | −€156.4M | €19.6M | −€49.1M | €4.1M | €22.9M | −€62.0M | €25.7M |
| Income taxes | €130,000 | €70,000 | €666,000 | −€17.5M | €26,000 | −€1.8M | −€95,799 | −€561,575 | −€571,000 | −€573,633 | −€2.5M | −€592,195 |
| Net income | €2.1M | €14.5M | €782.1M | −€202.1M | −€105.7M | −€153.4M | €25.3M | −€50.4M | €9.0M | €90.2M | €157.6M | €25.8M |
| EBITDA | −€40.5M | €14.0M | €560.5M | €2.4M | −€101.1M | −€158.7M | −€81.0M | −€61.4M | −€45.6M | −€42.9M | −€35.0M | −€27.7M |
| Gross margin | −185.8% | 26.0% | 99.9% | 84.8% | 92.8% | 81.7% | −49.6% | −55.5% | −15.8% | 518.5% | — | −164.8% |
| Operating margin | −358.9% | −982.9% | 84.2% | −58.6% | −87.3% | −211.7% | −107.4% | −90.7% | −49.0% | −53.1% | — | −25.2% |
| Net margin | 17.4% | 223.6% | 86.8% | −284.0% | −162.0% | −204.6% | 33.5% | −84.3% | 11.5% | 144.5% | — | 21.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in euros as reported in LKFT's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
LKFT financial results
In fiscal year 2025 (ended December 31, 2025), Lakefront Biotherapeutics reported revenue of €1.1 billion, up 303.5% from the year before. It had net income of €320.9 million (up 333.1%), a net profit margin of 28.9%. Figures are in euros, the currency of its financial statements.
See the LKFT stock overview for the latest quote and news, or the LKFT chart for price history and technical indicators.
LKFT income statement FAQ
What is Lakefront Biotherapeutics's annual revenue?
Lakefront Biotherapeutics reported total revenue of €1.1 billion for fiscal year 2025, which ended on December 31, 2025. That was up 303.5% from €275.6 million the previous year.
Is Lakefront Biotherapeutics profitable?
Yes. Lakefront Biotherapeutics reported net income of €320.9 million in fiscal 2025, a net profit margin of 28.9%; its operating margin was 45.1%.
What is Lakefront Biotherapeutics's gross margin?
Lakefront Biotherapeutics's gross margin was 97.3% in fiscal 2025: for every $100 of revenue, Lakefront Biotherapeutics kept $97 after the direct cost of its products and services.
How much does Lakefront Biotherapeutics spend on research and development?
Lakefront Biotherapeutics spent €459.4 million on research and development in fiscal 2025, 41.3% of revenue.
When does Lakefront Biotherapeutics's fiscal year end?
Lakefront Biotherapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.